- Stocks
- Healthcare
- NASDAQ: CORT

Price (delayed)

$35.08

Market cap

$3.65B

P/E Ratio

30.5

Dividend/share

N/A

EPS

$1.15

Enterprise value

$3.5B

Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym®

Corcept Therapeutics's debt has shrunk by 87% YoY and by 50% QoQ

The EPS has grown by 31% year-on-year and by 13% since the previous quarter

The quick ratio is up by 24% since the previous quarter but it is down by 23% year-on-year

The P/E is 32% more than the 5-year quarterly average of 22.7 and 9% more than the last 4 quarters average of 27.4

What are the main financial stats of CORT

Market
Valuations
Earnings

Shares outstanding

104.11M

Market cap

$3.65B

Enterprise value

$3.5B

Price to book (P/B)

6.63

Price to sales (P/S)

6.89

EV/EBIT

28.93

EV/EBITDA

28.5

EV/Sales

6.69

Revenue

$523.53M

EBIT

$121.09M

EBITDA

$122.89M

Free cash flow

$124.7M

Per share
Balance sheet
Liquidity

EPS

$1.15

Free cash flow per share

$1.21

Book value per share

$5.29

Revenue per share

$5.09

TBVPS

$6.38

Total assets

$655.94M

Total liabilities

$108.07M

Debt

$76,000

Equity

$547.86M

Working capital

$406.17M

Debt to equity

0

Current ratio

5.18

Quick ratio

4.86

Net debt/EBITDA

-1.22

Margins
Efficiency
Dividend

EBITDA margin

23.5%

Gross margin

98.5%

Net margin

22.4%

Operating margin

23.3%

Return on assets

19.6%

Return on equity

24.2%

Return on invested capital

34.3%

Return on capital employed

21.7%

Return on sales

23.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Corcept Therapeutics stock price performed over time

Intraday

1.74%

1 week

5.38%

1 month

15.43%

1 year

43.95%

YTD

8%

QTD

7.97%

How have Corcept Therapeutics's revenue and profit performed over time

Revenue

$523.53M

Gross profit

$515.9M

Operating income

$121.93M

Net income

$117.19M

Gross margin

98.5%

Net margin

22.4%

The revenue rose by 27% year-on-year and by 9% since the previous quarter

The gross profit is up by 26% year-on-year and by 8% since the previous quarter

CORT's net income is up by 24% YoY and by 11% QoQ

Corcept Therapeutics's operating income has increased by 21% YoY and by 14% from the previous quarter

What is Corcept Therapeutics's growth rate over time

What is Corcept Therapeutics stock price valuation

P/E

30.5

P/B

6.63

P/S

6.89

EV/EBIT

28.93

EV/EBITDA

28.5

EV/Sales

6.69

The P/E is 32% more than the 5-year quarterly average of 22.7 and 9% more than the last 4 quarters average of 27.4

The EPS has grown by 31% year-on-year and by 13% since the previous quarter

The stock's price to book (P/B) is 30% more than its 5-year quarterly average of 5.0 and 14% more than its last 4 quarters average of 5.7

The company's equity rose by 8% QoQ and by 3.5% YoY

The revenue rose by 27% year-on-year and by 9% since the previous quarter

CORT's P/S is 15% above its last 4 quarters average of 5.9 and 11% above its 5-year quarterly average of 6.1

How efficient is Corcept Therapeutics business performance

CORT's ROIC is up by 30% year-on-year

The return on equity is up by 25% year-on-year and by 10% since the previous quarter

CORT's return on assets is up by 16% year-on-year and by 9% since the previous quarter

The return on sales has declined by 4.9% year-on-year but it has grown by 4.5% since the previous quarter

What is CORT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CORT.

How did Corcept Therapeutics financials performed over time

The quick ratio is up by 24% since the previous quarter but it is down by 23% year-on-year

The company's current ratio fell by 23% YoY but it rose by 18% QoQ

Corcept Therapeutics's debt is 100% lower than its equity

Corcept Therapeutics's debt has shrunk by 87% YoY and by 50% QoQ

The company's equity rose by 8% QoQ and by 3.5% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.